Shenzhen YHLO Biotech Co., Ltd.
688575.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.98B
Close$
$-5.34
151.1% downside
Current Fair Value
151.1% downsideOvervalued by 151.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.98 Billion |
|---|---|
| Enterprise Value | $6.43 Billion |
| Dividend Yield | $0.02 (0.20%) |
| Earnings per Share | $0.04 |
| Beta | 0.21 |
| Outstanding Shares | 571,388,300 |
Return
| Return on Equity | 2.47% |
|---|---|
| Return on Assets | 1.56% |
| Return on Invested Capital | 5.08% |
Valuation & Multiples
| P/E Ratio | 79.48 |
|---|---|
| PEG | 35.54 |
| Price to Sales | 3.49 |
| Price to Book Ratio | 2.62 |
| Enterprise Value to Revenue | 3.4 |
| Enterprise Value to EBIT | 37.05 |
| Enterprise Value to Net Income | 94 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$490.14 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$501.81 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shenzhen YHLO Biotech Co., Ltd.
1,689 employees
CEO: Yong Bo Song Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. The company offers chemiluminescence immunoassay analyzer, diabetes solution, ...